Experimental drug DCR-STAT3 tested in patients with stubborn cancers

NCT ID NCT06098651

Completed Disease control Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested an experimental drug called DCR-STAT3 in 26 adults with solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. Researchers gave increasing doses to find the best and safest amount.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DCR-STAT3 (an experimental drug given intravenously)
What this could lead to: If successful, this could lead to a new treatment option for patients with hard-to-treat solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early (Phase 1) trial with only 26 participants, so safety and dosing are still being figured out. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm non-Hodgkin lymphoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY TUMOR SOLID TUMOR, ADULT

Contacts and locations

Locations

Next Oncology

Dallas, Texas, 75039, United States
Next Oncology

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.